魚津 桜子

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Cisplatin 60%
3. Bronchi 47%
4. Bronchoscopy 34%
5. Afatinib 34%
6. Lung Neoplasms 33%
7. ErbB Receptors 33%
8. Vinorelbine 29%
9. Pemetrexed 29%
10. Safety 28%
11. Gefitinib 28%
12. Continuous Ambulatory Peritoneal Dialysis 27%
13. Biopsy 27%
14. Thymoma 26%
15. Midazolam 25%
16. Sarcoidosis 24%
17. Sleep Apnea Syndromes 24%
18. Silicones 24%
19. Lymphadenopathy 23%
20. Adjuvant Chemotherapy 22%
21. Magnesium 22%
22. Metabolic Syndrome 20%
23. Protein-Tyrosine Kinases 20%
24. Neoplasm Metastasis 20%
25. Retrospective Studies 20%
26. Pharmacokinetics 19%
27. Renal Dialysis 19%
28. Mutation 19%
29. Tomography 18%
30. Observational Studies 17%
31. Lymphocytes 15%
32. Fistula 15%
33. Hemoptysis 13%
34. Creatinine 12%
35. Ultrasonography 12%
36. Lymph Nodes 12%
37. Lung 11%
38. Adenocarcinoma of Lung 11%
39. Liver 11%
40. Febrile Neutropenia 10%
41. Chronic Kidney Failure 9%
42. Response Evaluation Criteria in Solid Tumors 9%
43. CD4-CD8 Ratio 9%
44. Therapeutics 9%
45. Leukopenia 8%
46. Needles 8%
47. Ascites 8%
48. Drug Therapy 8%
49. Recurrence 8%
50. Transaminases 8%